Prompt onset of Rowell's syndrome following the first BNT162b2 SARS‐CoV‐2 vaccination

Cutaneous Adverse Reactions to COVID-19 Vaccines: Insights from an Immuno-Dermatological Perspective

“…We recently reported worsening disease in a patient with longstanding subacute CLE after the first dose of BNT162b2 [26]. Moreover, there are reports about Rowell's syndrome (RS)-i.e., a rare subtype of CLE with features of erythema multiforme (EM)-or annular plaques resembling RS in the course of mRNA vaccines [34,45]. Notably, development of annular lesions has also been described with a COVID-19 vector vaccine, which could be interpreted as a lupus-like reaction in our opinion [46].…”

“…Apart from the role of IFN-γ, there might be other CLE-triggering components in different COVID-19 vaccines. Gambichler et al speculated about a potential role of PEGs, because similar lupus-like reactions have been described with PEGylated liposomal doxorubicin in the past [ 45 ]. Even though safety data are limited, vaccination against COVID-19 is desirable in almost all patients suffering from rheumatic conditions, including CLE patients [ 49 , 50 ].…”

Cutaneous lymphocytic vasculitis after administration of COVID ‐19 mRNA vaccine

“…New insights about cross‐reactivity between human tissue and SARS‐CoV‐2 have been recently demonstrated and the possibility of development of autoimmune disease reported. 4 , 5 Immune response against the viral antigen following infection or vaccination can react with human tissue because of mimicry. 4 The involvement of the vessel might explain the late vascular side effect such as chilblain eruption.…”

Can SARS‐CoV‐2 vaccine increase the risk of reactivation of Varicella zoster? A systematic review

“…Clinical studies have reported that the most common cutaneous adverse effects are injection site reaction and pruritus; allergic reactions such as urticaria and widespread erythematous rash 4 . In the literature, various cutaneous conditions have been observed including anecdotal cases of erythema multiforme with morbilliform rash, delayed‐type hypersensitivity reaction, bullous drug eruption, pernio/chilblains (eg, “COVID toes”), erythromelalgia, and pityriasis‐rosea‐like exanthems, and herpes zoster (HZ) 5‐8 . Studies have reported development of herpes zoster due to SARS‐CoV‐2 infection either at the time of disease progression or following recovery from the disease.…”